RxDoctor Payments Data

Darla Melton, NP

Family · Roswell, NMNPI 1063934818

Payments from drug & device makers

$1,572in general payments, 2019–2025

Across 82 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$475
  • Intercept Pharmaceuticals, Inc.$296
  • AstraZeneca$254
  • Biogen$118
  • Bristol Myers Squibb$80
  • Merck$45
  • plus $304 from 12 others

What the payments were for

  • Food & beverage$1,572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,572 in reported general payments places this provider in the 85th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$49,681
Medicare patients
207
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$27,905
LinzessLinaclotide21$15,795
OzempicSemaglutide14$14,179
Pantoprazole Sodium383$7,295
Dexlansoprazole DrDexlansoprazole11$3,770
Esomeprazole Magnesium43$2,603
Famotidine121$1,760
Ventolin HfaAlbuterol Sulfate16$1,388
Lansoprazole34$1,325
Levothyroxine Sodium75$1,121
CholestyramineCholestyramine (With Sugar)19$886
Sucralfate31$881
Omeprazole80$822
Atorvastatin Calcium65$762
Dicyclomine Hcl39$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$40$27,90529 claims
AbbVieLinzess$475$15,79521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,080 family providers in New Mexico.

Other family in Roswell

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →